Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA V's Next Stop Is An Oct. 24 Public Hearing; FDA Hopes Final Stop Is 129 New FTEs

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposed user fee deal will get public input one last time before going to Congress.

You may also be interested in...



Harkin Eyes Inspection Fees For Drug, Ingredient Manufacturers

Sen. Tom Harkin is considering a fee on drug firms to pay for facility inspections.

Harkin Eyes Inspection Fees For Drug, Ingredient Manufacturers

Sen. Tom Harkin is considering a fee on drug firms to pay for facility inspections.

PDUFA V Commitment Letter Front-Loads Guidance, Meeting Milestones

It may not feel like it to exhausted user fee negotiators, but the release of FDA’s draft commitment letter for PDUFA V signals the start of more long campaigns for the agency and pharmaceutical companies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel